Host |
Mouse |
Klon |
DBM15.28 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Histiocytoma, colon, pancreas |
Verdünnung |
- |
Isotyp |
IgM kappa |
Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
25 ml |
Ready-to-use |
CE/IVD |
PDM230-25 |
-
|
Host |
Mouse |
Klon |
31 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Cervix, tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human Topo Iiα aa 1245-1361 |
Lokalisation |
Nuclear |
Topoisomerase II alpha
|
Biocare Medical |
31 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3045A |
-
|
Host |
Mouse |
Klon |
31 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Cervix, tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human Topo Iiα aa 1245-1361 |
Lokalisation |
Nuclear |
Topoisomerase II alpha
|
Biocare Medical |
31 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3045B |
-
|
Host |
Mouse |
Klon |
31 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Cervix, tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human Topo Iiα aa 1245-1361 |
Lokalisation |
Nuclear |
Topoisomerase II alpha
|
Biocare Medical |
31 |
6 ml |
Ready-to-use |
CE/IVD |
API3045AA |
-
|
Host |
Goat |
Klon |
polyclonal |
Format |
Purified |
Methode |
IF |
Isotyp |
Goat IgG |
Verdünnung |
RH strain of Toxoplasma Gondii |
Toxoplasma gondii
|
Zytomed Systems GmbH |
polyclonal |
1 mg |
Purified |
RUO |
620-0203 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P, F |
Vorbehandlung |
EDTA |
Positivkontrolle |
Infected tissue |
Verdünnung |
1:25 - 1:100 |
Isotyp |
IgG |
Lokalisation |
Cell wall |
Toxoplasma gondii
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK068-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Toxoplasma Gondii infected tissue. |
Verdünnung |
1:10 - 1:30 |
Isotyp |
IgG |
Verdünnung |
Toxoplasma gondii |
Lokalisation |
Organisms |
Toxoplasma gondii
|
Zeta Corporation |
polyclonal |
1.0 ml |
Concentrate |
RUO |
Z2556RL-R |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Toxoplasma Gondii infected tissue. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Toxoplasma gondii |
Lokalisation |
Organisms |
Toxoplasma gondii
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
RUO |
Z2556RP-R |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Toxoplasma Gondii infected tissue. |
Verdünnung |
1:10 - 1:30 |
Isotyp |
IgG |
Verdünnung |
Toxoplasma gondii |
Lokalisation |
Organisms |
Toxoplasma gondii
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
RUO |
Z2556RS-R |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Toxoplasma Gondii infected tissue. |
Verdünnung |
1:10 - 1:30 |
Isotyp |
IgG |
Verdünnung |
Toxoplasma gondii |
Lokalisation |
Organisms |
Toxoplasma gondii
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
RUO |
Z2556RT-R |
-
|
Host |
Monospecific Mouse |
Klon |
ZM174 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Hairy cell leukemia. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human ACP5 protein |
Lokalisation |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
1 ml |
Concentrate |
CE/IVD |
Z2486ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM174 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Hairy cell leukemia. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human ACP5 protein |
Lokalisation |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
7 ml |
Ready-to-use |
CE/IVD |
Z2486MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM174 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Hairy cell leukemia. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human ACP5 protein |
Lokalisation |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
0.5 ml |
Concentrate |
CE/IVD |
Z2486MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM174 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Hairy cell leukemia. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human ACP5 protein |
Lokalisation |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
0.1 ml |
Concentrate |
CE/IVD |
Z2486MT |
-
|
Host |
Rabbit |
Klon |
ZR243 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
Lokalisation |
cell membrane |
TRAcP
|
Zeta Corporation |
ZR243 |
0.1 ml |
Concentrate |
CE/IVD |
Z2714RT |
-
|
Host |
Mouse |
Klon |
5G63 |
Format |
Culture Supernatant |
Methode |
IHC(P) |
Vorbehandlung |
Citrat pH 6.0 |
Positivkontrolle |
Placenta |
Verdünnung |
1:20 - 1:40 |
Isotyp |
mouse |
Transferrin Receptor (CD71)
|
Zytomed Systems GmbH |
5G63 |
500 µL |
Culture Supernatant |
RUO |
103-2299 |
-
|
Host |
Mouse |
Klon |
TB21 |
Format |
Purified |
Methode |
F, P, EL |
Positivkontrolle |
Human breast carcinoma |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human transforming groth factor beta 1 from platelets |
Transforming Growth Factor beta (TGFb)
|
Zytomed Systems GmbH |
TB21 |
100 µg |
Purified |
RUO |
620-0255 |
-
|
Host |
Mouse |
Klon |
TB21 |
Format |
Purified |
Methode |
F, P |
Positivkontrolle |
Human breast carcinoma |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human transforming groth factor beta 1 from platelets |
Transforming Growth Factor beta (TGFb)
|
Zytomed Systems GmbH |
TB21 |
10 µg |
Purified |
RUO |
620-0256 |
-
|
Host |
Mouse |
Klon |
CUB7402 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
1 ml |
Concentrate |
CE/IVD |
MOB353 |
-
|
Host |
Mouse |
Klon |
CUB7402 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
0.1 ml |
Concentrate |
CE/IVD |
MOB353-01 |
-
|
Host |
Mouse |
Klon |
CUB7402 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
0.5 ml |
Concentrate |
CE/IVD |
MOB353-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
ER1 |
Positivkontrolle |
Lymphoma, Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane |
TRBC1
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3280G7 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
P, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
infected tissue |
Isotyp |
Rabbit IgG |
Verdünnung |
Native, purified |
Treponema pallidum
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
620-0262 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Verdünnung |
1:100 - 1:200 |
Verdünnung |
Treponema pallidum |
Lokalisation |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
1ml |
Concentrate |
RUO |
Z2554RL-R |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Verdünnung |
- |
Verdünnung |
Treponema pallidum |
Lokalisation |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
RUO |
Z2554RP-R |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Verdünnung |
1:100 - 1:200 |
Verdünnung |
Treponema pallidum |
Lokalisation |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
RUO |
Z2554RS-R |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Verdünnung |
1:100 - 1:200 |
Verdünnung |
Treponema pallidum |
Lokalisation |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
RUO |
Z2554RT-R |
-
|
Host |
Mouse |
Klon |
1306/156 |
Format |
Purified |
Methode |
EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Native |
Trichomonas vaginalis (Strain 1)
|
Zytomed Systems GmbH |
1306/156 |
200 µg |
Purified |
RUO |
620-0265 |
-
|
Host |
Rabbit |
Klon |
EPR17341 |
Format |
Concentrate |
Methode |
P, IF, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Astrocytoma, cerebral cortex tissue |
Verdünnung |
1:500 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm |
TrkA + TrkB + TrkC
|
Abcam |
EPR17341 |
0.1 ml |
Concentrate |
RUO |
AB181560 |
-
|
Host |
Rabbit |
Klon |
SP293 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB, FL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP293 |
0.5 ml |
Concentrate |
RUO |
520-5932 |
-
|
Host |
Rabbit |
Klon |
SP293 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB, FL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP293 |
1 ml |
Concentrate |
RUO |
520-5934 |
-
|
Host |
Rabbit |
Klon |
SP294 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP294 |
0.5 ml |
Concentrate |
RUO |
520-5942 |
-
|
Host |
Rabbit |
Klon |
SP294 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP294 |
1 ml |
Concentrate |
RUO |
520-5944 |
-
|
Host |
Rabbit |
Klon |
SP295 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP295 |
0.5 ml |
Concentrate |
RUO |
520-5952 |
-
|
Host |
Rabbit |
Klon |
SP295 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP295 |
1 ml |
Concentrate |
RUO |
520-5954 |
-
|
Host |
Rabbit |
Klon |
ZR388 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast or colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
1 ml |
Concentrate |
CE/IVD |
Z2744RL |
-
|
Host |
Rabbit |
Klon |
ZR388 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast or colon carcinoma |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
7 ml |
ready-to-use |
CE/IVD |
Z2744RP |
-
|
Host |
Rabbit |
Klon |
ZR388 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast or colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
0.5 ml |
Concentrate |
CE/IVD |
Z2744RS |
-
|
Host |
Rabbit |
Klon |
ZR388 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast or colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
0.1 ml |
Concentrate |
CE/IVD |
Z2744RT |
-
|
Host |
Rabbit |
Klon |
ZR382 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast, breast carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
Lokalisation |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
1 ml |
Concentrate |
CE/IVD |
Z2673RL |
-
|
Host |
Rabbit |
Klon |
ZR382 |
Format |
r-t-u |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast, breast carcinoma |
Verdünnung |
gebrauchsfertig |
Isotyp |
IgG |
Verdünnung |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
Lokalisation |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
7 ml |
r-t-u |
CE/IVD |
Z2673RP |
-
|
Host |
Rabbit |
Klon |
ZR382 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast, breast carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
Lokalisation |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
0.5 ml |
Concentrate |
CE/IVD |
Z2673RS |
-
|
Host |
Rabbit |
Klon |
ZR382 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast, breast carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
Lokalisation |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
0.1 ml |
Concentrate |
CE/IVD |
Z2673RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P, WB, EL |
Vorbehandlung |
Fast Enzyme, Pepsin |
Positivkontrolle |
Pancreas |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified trypsin from human pancreas |
Lokalisation |
Cytoplasmic, extracellular |
Trypsin (Human pancreatic)
|
Zytomed Systems GmbH |
polyclonal |
0.2 ml |
Concentrate |
RUO |
RBK055-02 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anterior Pituitary |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified human TSH |
Lokalisation |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
520-17500 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anterior Pituitary |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified human TSH |
Lokalisation |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
520-17502 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anterior Pituitary |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified human TSH |
Lokalisation |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
520-17504 |
-
|
Host |
Mouse |
Klon |
8G7G3/1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal thyroid or lung. |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Rat TTF-1 recombinant protein |
Lokalisation |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2069ML |
-
|
Host |
Mouse |
Klon |
8G7G3/1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal thyroid or lung. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Rat TTF-1 recombinant protein |
Lokalisation |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2069MP |
-
|
Host |
Mouse |
Klon |
8G7G3/1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal thyroid or lung. |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Rat TTF-1 recombinant protein |
Lokalisation |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2069MS |
-
|